These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20739521)

  • 21. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.
    Yi M; Tong X; Skelton A; Chase R; Chen T; Prongay A; Bogen SL; Saksena AK; Njoroge FG; Veselenak RL; Pyles RB; Bourne N; Malcolm BA; Lemon SM
    J Biol Chem; 2006 Mar; 281(12):8205-15. PubMed ID: 16352601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of naturally occurring 5' non-translated region variants of hepatitis C virus genotype 1b in selectable replicons.
    van Leeuwen HC; Reusken CBEM; Roeten M; Dalebout TJ; Riezu-Boj JI; Ruiz J; Spaan WJM
    J Gen Virol; 2004 Jul; 85(Pt 7):1859-1866. PubMed ID: 15218170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
    Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients.
    Cao Y; Bao Y; Xia W; Wu H; Wei F; Zhang Y; Zhang R; Xu X
    Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):597-604. PubMed ID: 27016893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
    Fevery B; Verbinnen T; Peeters M; Janssen K; Witek J; Jessner W; De Meyer S; Lenz O
    J Viral Hepat; 2017 Jan; 24(1):28-36. PubMed ID: 27696653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.
    Verbinnen T; Jacobs T; Vijgen L; Ceulemans H; Neyts J; Fanning G; Lenz O
    J Antimicrob Chemother; 2012 Oct; 67(10):2327-37. PubMed ID: 22723600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals.
    Robinson M; Tian Y; Delaney WE; Greenstein AE
    Proc Natl Acad Sci U S A; 2011 Jun; 108(25):10290-5. PubMed ID: 21646519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
    Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.
    Liang Y; Ishida H; Lenz O; Lin TI; Nyanguile O; Simmen K; Pyles RB; Bourne N; Yi M; Li K; Lemon SM
    Gastroenterology; 2008 Nov; 135(5):1710-1718.e2. PubMed ID: 18725224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors.
    Delang L; Vliegen I; Leyssen P; Neyts J
    J Hepatol; 2012 Jan; 56(1):41-8. PubMed ID: 21703175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.
    Sarrazin C; Kieffer TL; Bartels D; Hanzelka B; Müh U; Welker M; Wincheringer D; Zhou Y; Chu HM; Lin C; Weegink C; Reesink H; Zeuzem S; Kwong AD
    Gastroenterology; 2007 May; 132(5):1767-77. PubMed ID: 17484874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.
    Lawitz E; Yang JC; Stamm LM; Taylor JG; Cheng G; Brainard DM; Miller MD; Mo H; Dvory-Sobol H
    Antivir Ther; 2018; 23(4):325-334. PubMed ID: 29063860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
    Tong X; Arasappan A; Bennett F; Chase R; Feld B; Guo Z; Hart A; Madison V; Malcolm B; Pichardo J; Prongay A; Ralston R; Skelton A; Xia E; Zhang R; Njoroge FG
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2365-70. PubMed ID: 20308381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
    Lawitz EJ; Hill JM; Marbury T; Demicco MP; Delaney W; Yang J; Moorehead L; Mathias A; Mo H; McHutchison JG; Rodriguez-Torres M; Gordon SC
    Antivir Ther; 2013; 18(3):311-9. PubMed ID: 23047118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.